Announcements Trials
Browse Landscape

Status

Available 1

Sponsor Class

OTHER 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

3-Iodobenzylguanidine 4tempol 2balstilimab 2zolbetuximab 1zipalertinib 1venetoclax 1ulixertinib 1tisagenlecleucel 1tipifarnib 1tebentafusp 1talazoparib 1sodium thiosulfate 1selinexor 1ruxolitinib 1ribociclib 1osunprotafib 1nirogacestat 1mirdametinib 1mifamurtide 1lifileucel 1leronlimab 1idecabtagene vicleucel 1gedatolisib 1fluorodopa F 18 1fluorocholine 1epigallocatechin gallate 1ensartinib 1dodecyl maltoside 1carbon-11 methionine 1burosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Available × Expanded_access × Dasatinib × Clear all
NCT00854841 2009-03-03

The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder

Pusan National University Hospital

Available
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡